Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NKTX 
Nkarta Inc (NKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NKTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.4
1 Year Target Price $12.4
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 340.08% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.09M USD | Price to earnings Ratio - | 1Y Target Price 12.4 |
Price to earnings Ratio - | 1Y Target Price 12.4 | ||
Volume (30-day avg) 7 | Beta 0.73 | 52 Weeks Range 1.31 - 6.63 | Updated Date 08/29/2025 |
52 Weeks Range 1.31 - 6.63 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.35 | Actual -0.31 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.38% | Return on Equity (TTM) -26.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -52050094 | Price to Sales(TTM) 1000000 |
Enterprise Value -52050094 | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 1000000 | Enterprise Value to EBITDA 0.95 | Shares Outstanding 71024496 | Shares Floating 52511263 |
Shares Outstanding 71024496 | Shares Floating 52511263 | ||
Percent Insiders 5.02 | Percent Institutions 86.49 |
Upturn AI SWOT
Nkarta Inc
Company Overview
History and Background
Nkarta, Inc. was founded in 2015. It's a biopharmaceutical company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer. The company has advanced through preclinical stages and is currently in clinical trials for several of its NK cell therapy candidates.
Core Business Areas
- Cell Therapy Development: Nkarta focuses on discovering, developing, and manufacturing allogeneic, off-the-shelf NK cell therapies for various cancers.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its NK cell therapy candidates.
- Manufacturing: Developing proprietary manufacturing processes for large-scale production of NK cells.
Leadership and Structure
The company's leadership team consists of a CEO, CFO, CSO, and other key executives. The organizational structure includes research, development, clinical operations, manufacturing, and administrative departments.
Top Products and Market Share
Key Offerings
- NKT-101: An off-the-shelf NK cell therapy targeting NKG2D ligands expressed on cancer cells. Currently in Phase 1 clinical trials for relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). Market share data unavailable due to its development stage. Competitors include companies developing similar NK cell therapies.
- NKT-212: An off-the-shelf NK cell therapy designed to enhance anti-tumor activity through increased ADCC (antibody-dependent cell-mediated cytotoxicity). Currently in clinical trials. Market share data unavailable due to its development stage. Competitors include companies developing similar NK cell therapies.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, with significant investment in research and development of novel therapies for cancer and other diseases. There's increasing interest in NK cell therapies as a potentially safer and more effective alternative to other cell-based immunotherapies.
Positioning
Nkarta is positioned as an innovator in the allogeneic NK cell therapy space. Its competitive advantage lies in its proprietary technology platform and manufacturing capabilities.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to be in the tens of billions of dollars and is expected to grow significantly. Nkarta is positioned to capture a portion of this market through its pipeline of NK cell therapy candidates.
Upturn SWOT Analysis
Strengths
- Proprietary NK cell therapy platform
- Off-the-shelf allogeneic approach
- Strong intellectual property portfolio
- Experienced management team
- Clinical trial progress
Weaknesses
- Early-stage clinical development
- High development costs
- Dependence on clinical trial success
- Manufacturing complexities
- Limited commercialization experience
Opportunities
- Expanding clinical indications
- Partnering with pharmaceutical companies
- Advancements in manufacturing technology
- Positive clinical trial data
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles
- Manufacturing challenges
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- GILD
- BMY
Competitive Landscape
Nkarta faces competition from companies developing various cell therapies, including CAR-T cell therapies and other NK cell therapies. Its advantage lies in its allogeneic approach and proprietary technology, but it must demonstrate clinical efficacy to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Nkarta's historical growth is characterized by advancing its NK cell therapy programs through preclinical and clinical development.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization efforts. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing its NKT-101 and NKT-212 programs in clinical trials, optimizing manufacturing processes, and exploring potential partnerships.
Summary
Nkarta is a promising clinical-stage biotech company focused on allogeneic NK cell therapies, offering a novel approach to cancer treatment. Its strengths include its technology and progress in clinical trials, but it faces the inherent risks of drug development, including clinical trial failures and regulatory hurdles. Securing partnerships and navigating the competitive landscape will be crucial for Nkarta's success. It needs to focus on clinical trial efficiency and manage its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nkarta Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-10 | CEO & Director Mr. Paul J. Hastings | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.nkartatx.com |
Full time employees 110 | Website https://www.nkartatx.com | ||
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.